- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00960518
TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC) (TACE)
Combination Therapy With TACE and Adefovir Compared With TACE Alone for HBV-related Unresectable Hepatocellular Carcinoma
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies in China, and approximately 90% of the patients with HCC are also infected with hepatitis B virus (HBV). Until now, no standard therapy has been established for treatment of hepatocellular carcinoma. For patients with unresectable disease, the goal of palliative treatment is to control symptoms and prolong survival. Transarterial chemoembolization (TACE) using iodized oil and chemotherapeutic agents combines the effect of targeted chemotherapy with that of ischemic necrosis induced by arterial embolization. It can be administered repeatedly and can prolong survival in patients with unresectable hypervascular HCC. The long-term prognosis, however, remains guarded because of frequent development of locoregional tumor recurrence, which, together with concomitant hepatic decompensation, is the main cause of death. Recurrence in the liver remnant may originate from metastasis from the primary tumor or multicentric new primaries in a cirrhotic liver.
Adefovir works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body. It is approved for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (primarily ALT) or histologically active disease. The main benefit of adefovir over lamivudine (the first NRTI approved for the treatment of hepatitis B) is that it takes a much longer period of time before the virus develops resistance to it. Adefovir dipivoxil contains two pivaloyloxymethyl units, making it a prodrug form of Adefovir.
Based on these results, the investigators conducted a randomized controlled trial to test the hypothesis that adefovir treatment would reduce or postpone the recurrence rate and improve the overall survival rate in patients after TACE treatment of HBV-related unresectable HCC.
Studietype
Registrering (Forventet)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Daoyuan Wang, MD
- Telefonnummer: +86-21-6630058
- E-post: ghealth2008@gmail.com
Studiesteder
-
-
Heilongjiang
-
Ha'er'bin, Heilongjiang, Kina, 150001
- Rekruttering
- The Fourth Affiliated Hospital of Haerbin Medical University
-
Ta kontakt med:
- Baozhong Shen, MD
- Telefonnummer: +86-451-82576888
- E-post: drbaozhong.shen@gmail.com
-
Hovedetterforsker:
- Baozhong Shen, MD
-
-
Shanghai
-
Shanghai, Shanghai, Kina, 200025
- Rekruttering
- Shanghai 10th Hospital of Tongji University
-
Ta kontakt med:
- Maoquan Li, MD, PhD
- Telefonnummer: +86-21-6630058
- E-post: drmaoquan.li@gmail.com
-
Hovedetterforsker:
- Maoquan Li, MD, PhD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- age:20-75 years old
- with a clinical diagnosis of primary liver cancer, with HBsAg positive,without any therapy for tumor
- single lesion with a diameter >6.5 cm,or multiple lesions locating within half liver or adjacent three lobe
- estimated liver remnant volume ≤40%
- with a liver function of Child-Pugh class A,and ALT≤80IU/l.
Exclusion Criteria:
- reject to attend
- portal vein trunk has been compressed by tumor
- diffuse type cancer or with extensive cancer thrombus in main branches of PV,HV,IVC or bile duct
- with extrahepatic metastasis
- with obvious portal hypertension (with moderate to severe varix in esophagus and/or gastric fundus, enlarged spleen,WBC<4×109/L, PLT<80×109/L)
- with diabetes
- allergy to iodine
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Placebo komparator: TACE
An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance.
The injection could be slowed or discontinued if retrograde flow occurred.
Embolization was subsequently performed with granules of gelatin sponge particles.
|
An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance.
The injection could be slowed or discontinued if retrograde flow occurred.
Embolization was subsequently performed with granules of gelatin sponge particles.
|
Eksperimentell: TACE+adefovir
patients received adefovir, at a dose of 10 mg daily after TACE treatment, for 48 weeks
|
adefovir at 10 mg daily for 48 weeks
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
the progression free survival (PFS)
Tidsramme: 3 months
|
3 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
the rate of overall survival
Tidsramme: 1, 3, 5 years
|
1, 3, 5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studiestol: Maoquan Li, MD, PhD, Interventional Radiology Research Group, Shanghai Radiology Society
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Neoplasmer etter histologisk type
- Neoplasmer
- Neoplasmer etter nettsted
- Adenokarsinom
- Neoplasmer, kjertel og epitel
- Neoplasmer i fordøyelsessystemet
- Leversykdommer
- Hepatitt, viral, menneskelig
- Hepadnaviridae-infeksjoner
- DNA-virusinfeksjoner
- Neoplasmer i leveren
- Enterovirusinfeksjoner
- Picornaviridae-infeksjoner
- Karsinom
- Hepatitt B
- Hepatitt
- Karsinom, hepatocellulært
- Hepatitt A-virus
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Revers transkriptasehemmere
- Nukleinsyresyntesehemmere
- Enzymhemmere
- Adefovir
Andre studie-ID-numre
- SHDSYY20090725
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på TACE
-
AZ-VUBUkjentDiabetes mellitus, type 1Belgia
-
Novartis PharmaceuticalsFullført
-
Tallac TherapeuticsRekrutteringAvanserte eller metastatiske solide svulsterForente stater, Australia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Taiho Pharmaceutical Co., Ltd.FullførtLeverkreftForente stater
-
Taiho Pharmaceutical Co., Ltd.FullførtOveraktiv blære | Detrusor-underaktivitetJapan
-
Weill Medical College of Cornell UniversityNational Cancer Institute (NCI)FullførtAvansert kreftForente stater
-
Taiho Oncology, Inc.Quintiles, Inc.Avsluttet
-
Chia Nan University of Pharmacy & ScienceGlac Biotech Co., LtdFullført
-
Taiho Oncology, Inc.TilbaketrukketAvansert hepatocellulært karsinom
-
Novartis PharmaceuticalsTilbaketrukket